Immix Biopharma (NASDAQ:IMMX) Price Target Raised to $27.00

Immix Biopharma (NASDAQ:IMMX – Free Report) had its target price boosted by HC Wainwright from $25.00 to $27.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.24) EPS and FY2027 earnings at ($0.86) EPS.

Several other equities research analysts have also recently commented on IMMX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Morgan Stanley reiterated an “overweight” rating on shares of Immix Biopharma in a research report on Tuesday, October 20th. Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a research note on Wednesday, September 30th. Needham & Company LLC upped their target price on Immix Biopharma from $21.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Finally, Mizuho set a $23.00 target price on Immix Biopharma in a research note on Thursday, October 29th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.14.

Check Out Our Latest Stock Report on Immix Biopharma

Immix Biopharma Trading Down 1.2%

IMMX stock opened at $7.11 on Monday. The company has a market cap of $595.89 million, a price-to-earnings ratio of -8.57 and a beta of 0.29. Immix Biopharma has a 12 month low of $3.78 and a 12 month high of $15.10. The firm has a 50-day moving average of $9.46 and a two-hundred day moving average of $9.60.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). As a group, equities analysts forecast that Immix Biopharma will post -0.75 earnings per share for the current year.

Institutional Trading of Immix Biopharma

Several hedge funds have recently made changes to their positions in the company. Aquatic Capital Management LLC purchased a new stake in shares of Immix Biopharma during the 3rd quarter valued at approximately $771,000. Mathes Company Inc. lifted its holdings in Immix Biopharma by 23.5% in the third quarter. Mathes Company Inc. now owns 13,150 shares of the company’s stock valued at $137,000 after acquiring an additional 2,500 shares during the last quarter. Marshall Wace LLP lifted its holdings in Immix Biopharma by 3.3% in the third quarter. Marshall Wace LLP now owns 1,854,215 shares of the company’s stock valued at $19,284,000 after acquiring an additional 59,307 shares during the last quarter. Blue Owl Capital Holdings LP lifted its holdings in Immix Biopharma by 37.6% in the third quarter. Blue Owl Capital Holdings LP now owns 602,047 shares of the company’s stock valued at $6,264,000 after acquiring an additional 164,495 shares during the last quarter. Finally, Voya Investment Management LLC purchased a new position in Immix Biopharma in the third quarter worth approximately $116,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Key Stories Impacting Immix Biopharma

These are some of the IMMX stories that stood out recently:

  • Positive Sentiment: Morgan Stanley raised its price target to $21 from $20 and maintained an Overweight rating, signaling continued confidence in the stock. Morgan Stanley analyst ratings
  • Positive Sentiment: HC Wainwright kept its Buy rating and $27 target. It also revised some loss estimates favorably, including narrowing projected losses for Q4 2026 and Q1–Q2 2027. HC Wainwright analyst outlook
  • Neutral Sentiment: Mizuho lowered its target to $22 from $23 but retained an Outperform rating. The target reduction is a modest setback, while the maintained rating remains supportive. Mizuho analyst ratings

About Immix Biopharma

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Further Reading

Analyst Recommendations for Immix Biopharma (NASDAQ:IMMX)

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.